ients considered at risk for liver disease -- and increase their chances for successful treatment. For example, 170 million people worldwide are infected with chronic hepatitis C and a significant number will develop cirrhosis, which is untreatable. Even if some risk factors are identified, there is no way to predict which patients will develop fibrosis, and successive liver biopsies in all these patients aren't possible. Non-invasive monitoring with MRE of those at risk would detect the problem early and help assess the effect of treatments.